Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow-derived mesenchymal stem cells (Army Medical University)
- Development stage
- Unknown
- Lead developer
- Royan Institute
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intramuscular
01
Overview
This investigational cell therapy consists of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) developed by researchers at the Third Military Medical University (Southwest Hospital) in Chongqing, China. It is specifically designed for the treatment of type 2 diabetic patients suffering from critical limb ischemia (CLI) and chronic foot ulcers. The therapy involves harvesting the patient's own mesenchymal stem cells from bone marrow, which are then expanded and administered via multiple intramuscular injections into the affected lower limb. The biological mechanism of action relies on the regenerative and paracrine properties of the MSCs, which secrete pro-angiogenic factors and cytokines that promote angiogenesis, improve local limb perfusion, and accelerate the healing of chronic ulcers. Clinical trial results have indicated that BM-MSC transplantation is more effective than bone marrow-derived mononuclear cells (BM-MNCs) or saline in improving clinical parameters such as the ankle-brachial index (ABI), transcutaneous oxygen pressure (TcO2), and overall ulcer healing rates.
- Other names
- BM-MSCsautologous bone marrow mesenchymal stem cellsbone marrow-derived mesenchymal stem cells
Beyond the preview
Go deeper on autologous bone marrow-derived mesenchymal stem cells (Army Medical University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow-derived mesenchymal stem cells (Army Medical University).